Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 133 to 137 of 137 entries
Sorted by: Best Match Show Resources per page
Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality.

medRxiv : the preprint server for health sciences

Silva J, Lucas C, Sundaram M, Israelow B, Wong P, Klein J, Tokuyama M, Lu P, Venkataraman A, Liu F, Mao T, Oh JE, Park A, Casanovas-Massana A, Vogels CBF, Muenker CM, Zell J, Fournier JB, Campbell M, Chiorazzi M, Ruiz Fuentes E, Petrone M, Kalinich CC, Ott IM, Watkins A, Moore AJ, Nakahata MI, Grubaugh ND, Farhadian S, Dela Cruz C, Ko A, Schulz WL, Ring AM, Ma S, Omer S, Wyllie AL, Iwasaki A.
PMID: 33442706
medRxiv. 2021 Jan 10; doi: 10.1101/2021.01.04.21249236.

While several clinical and immunological parameters correlate with disease severity and mortality in SARS-CoV-2 infection, work remains in identifying unifying correlates of coronavirus disease 2019 (COVID-19) that can be used to guide clinical practice. Here, we examine saliva and...

Cite
Silva J, Lucas C, Sundaram M, et al. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv. 2021;doi: 10.1101/2021.01.04.21249236.
Silva, J., Lucas, C., Sundaram, M., Israelow, B., Wong, P., Klein, J., Tokuyama, M., Lu, P., Venkataraman, A., Liu, F., Mao, T., Oh, J. E., Park, A., Casanovas-Massana, A., Vogels, C. B. F., Muenker, C. M., Zell, J., Fournier, J. B., Campbell, M., Chiorazzi, M., Ruiz Fuentes, E., Petrone, M., Kalinich, C. C., Ott, I. M., Watkins, A., Moore, A. J., Nakahata, M. I., Grubaugh, N. D., Farhadian, S., Dela Cruz, C., Ko, A., Schulz, W. L., Ring, A. M., Ma, S., Omer, S., Wyllie, A. L., & Iwasaki, A. (2021). Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.01.04.21249236
Silva, Julio, et al. "Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.01.04.21249236
Silva J, Lucas C, Sundaram M, Israelow B, Wong P, Klein J, Tokuyama M, Lu P, Venkataraman A, Liu F, Mao T, Oh JE, Park A, Casanovas-Massana A, Vogels CBF, Muenker CM, Zell J, Fournier JB, Campbell M, Chiorazzi M, Ruiz Fuentes E, Petrone M, Kalinich CC, Ott IM, Watkins A, Moore AJ, Nakahata MI, Grubaugh ND, Farhadian S, Dela Cruz C, Ko A, Schulz WL, Ring AM, Ma S, Omer S, Wyllie AL, Iwasaki A. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv. 2021 Jan 10; doi: 10.1101/2021.01.04.21249236. PMID: 33442706; PMCID: PMC7805468.
Copy Download .nbib Format: NLM
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.

Pediatric blood & cancer

Woods AD, Berlow NE, Ortiz MV, Dela Cruz F, Siddiquee A, Coutinho DF, Purohit R, Freier KET, Michalek JE, Lathara M, Matlock K, Srivivasa G, Royer-Pokora B, Veselska R, Kung AL, Keller C.
PMID: 34693628
Pediatr Blood Cancer. 2021 Oct 24;e29401. doi: 10.1002/pbc.29401. Epub 2021 Oct 24.

BACKGROUND: Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms tumor have been described: tumors lacking anaplasia (the favorable subtype) and tumors displaying anaplastic features (the unfavorable subtype). Children with favorable disease generally...

Cite
Woods AD, Berlow NE, Ortiz MV, et al. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatr Blood Cancer. 2021;e29401doi: 10.1002/pbc.29401.
Woods, A. D., Berlow, N. E., Ortiz, M. V., Dela Cruz, F., Siddiquee, A., Coutinho, D. F., Purohit, R., Freier, K. E. T., Michalek, J. E., Lathara, M., Matlock, K., Srivivasa, G., Royer-Pokora, B., Veselska, R., Kung, A. L., & Keller, C. (2021). Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatric blood & cancer, e29401. https://doi.org/10.1002/pbc.29401
Woods, Andrew D, et al. "Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor." Pediatric blood & cancer vol. (2021): e29401. doi: https://doi.org/10.1002/pbc.29401
Woods AD, Berlow NE, Ortiz MV, Dela Cruz F, Siddiquee A, Coutinho DF, Purohit R, Freier KET, Michalek JE, Lathara M, Matlock K, Srivivasa G, Royer-Pokora B, Veselska R, Kung AL, Keller C. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatr Blood Cancer. 2021 Oct 24;e29401. doi: 10.1002/pbc.29401. Epub 2021 Oct 24. PMID: 34693628.
Copy Download .nbib Format: NLM
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19.

Journal of inflammation research

Xie C, Li Q, Li L, Peng X, Ling Z, Xiao B, Feng J, Chen Z, Chang, Xie L, Dela Cruz CS, Sharma L.
PMID: 33833543
J Inflamm Res. 2021 Mar 30;14:1207-1216. doi: 10.2147/JIR.S304190. eCollection 2021.

BACKGROUND: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X...

Cite
Xie C, Li Q, Li L, et al. Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19. J Inflamm Res. 2021;14:1207-1216doi: 10.2147/JIR.S304190.
Xie, C., Li, Q., Li, L., Peng, X., Ling, Z., Xiao, B., Feng, J., Chen, Z., Chang, Xie, L., Dela Cruz, C. S., & Sharma, L. (2021). Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19. Journal of inflammation research, 141207-1216. https://doi.org/10.2147/JIR.S304190
Xie, Chunmei, et al. "Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19." Journal of inflammation research vol. 14 (2021): 1207-1216. doi: https://doi.org/10.2147/JIR.S304190
Xie C, Li Q, Li L, Peng X, Ling Z, Xiao B, Feng J, Chen Z, Chang, Xie L, Dela Cruz CS, Sharma L. Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19. J Inflamm Res. 2021 Mar 30;14:1207-1216. doi: 10.2147/JIR.S304190. eCollection 2021. PMID: 33833543; PMCID: PMC8020811.
Copy Download .nbib Format: NLM
Translational Strategies for Repotrectinib in Neuroblastoma.

Molecular cancer therapeutics

O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS.
PMID: 34482287
Mol Cancer Ther. 2021 Nov;20(11):2189-2197. doi: 10.1158/1535-7163.MCT-21-0126. Epub 2021 Sep 04.

Limited clinical data are available regarding the utility of multikinase inhibition in neuroblastoma. Repotrectinib (TPX-0005) is a multikinase inhibitor that targets ALK, TRK, JAK2/STAT, and Src/FAK, which have all been implicated in the pathogenesis of neuroblastoma. We evaluated the...

Cite
O'Donohue TJ, Ibáñez G, Coutinho DF, et al. Translational Strategies for Repotrectinib in Neuroblastoma. Mol Cancer Ther. 2021;20(11):2189-2197doi: 10.1158/1535-7163.MCT-21-0126.
O'Donohue, T. J., Ibáñez, G., Coutinho, D. F., Mauguen, A., Siddiquee, A., Rosales, N., Calder, P., Ndengu, A., You, D., Long, M., Roberts, S. S., Kung, A. L., & Dela Cruz, F. S. (2021). Translational Strategies for Repotrectinib in Neuroblastoma. Molecular cancer therapeutics, 20(11), 2189-2197. https://doi.org/10.1158/1535-7163.MCT-21-0126
O'Donohue, Tara J, et al. "Translational Strategies for Repotrectinib in Neuroblastoma." Molecular cancer therapeutics vol. 20,11 (2021): 2189-2197. doi: https://doi.org/10.1158/1535-7163.MCT-21-0126
O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS. Translational Strategies for Repotrectinib in Neuroblastoma. Mol Cancer Ther. 2021 Nov;20(11):2189-2197. doi: 10.1158/1535-7163.MCT-21-0126. Epub 2021 Sep 04. PMID: 34482287; PMCID: PMC8571000.
Copy Download .nbib Format: NLM
Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19.

Journal of immunology (Baltimore, Md. : 1950)

Hoehn KB, Ramanathan P, Unterman A, Sumida TS, Asashima H, Hafler DA, Kaminski N, Dela Cruz CS, Sealfon SC, Bukreyev A, Kleinstein SH.
PMID: 34049971
J Immunol. 2021 Jun 15;206(12):2785-2790. doi: 10.4049/jimmunol.2100135. Epub 2021 May 28.

Protective immunity against COVID-19 likely depends on the production of SARS-CoV-2-specific plasma cells and memory B cells postinfection or postvaccination. Previous work has found that germinal center reactions are disrupted in severe COVID-19. This may adversely affect long-term immunity...

Cite
Hoehn KB, Ramanathan P, Unterman A, et al. Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. J Immunol. 2021;206(12):2785-2790doi: 10.4049/jimmunol.2100135.
Hoehn, K. B., Ramanathan, P., Unterman, A., Sumida, T. S., Asashima, H., Hafler, D. A., Kaminski, N., Dela Cruz, C. S., Sealfon, S. C., Bukreyev, A., & Kleinstein, S. H. (2021). Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. Journal of immunology (Baltimore, Md. : 1950), 206(12), 2785-2790. https://doi.org/10.4049/jimmunol.2100135
Hoehn, Kenneth B, et al. "Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19." Journal of immunology (Baltimore, Md. : 1950) vol. 206,12 (2021): 2785-2790. doi: https://doi.org/10.4049/jimmunol.2100135
Hoehn KB, Ramanathan P, Unterman A, Sumida TS, Asashima H, Hafler DA, Kaminski N, Dela Cruz CS, Sealfon SC, Bukreyev A, Kleinstein SH. Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. J Immunol. 2021 Jun 15;206(12):2785-2790. doi: 10.4049/jimmunol.2100135. Epub 2021 May 28. PMID: 34049971; PMCID: PMC8627528.
Copy Download .nbib Format: NLM
Showing 133 to 137 of 137 entries